ALLO · Allogene Therapeutics, Inc. · Webcasts, Transcripts & Audio
$0.84
+0.01 (+1.41%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$290.58M
Shares
346.47M
Volume · Nov 13
11.66M
Avg daily vol (3M)
7.37M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Allogene Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Allogene Therapeutics, Inc. (ALLO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-12-02
Allogene Therapeutics, Inc. (ALLO) December 2, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-18
Allogene Therapeutics, Inc. (ALLO) November 18, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-11-16
Allogene Therapeutics, Inc. (ALLO) November 16, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-05
Allogene Therapeutics, Inc. (ALLO) Q3 2026 Earnings Call
Revenue
$0
Diluted EPS
$-0.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-09
Allogene Therapeutics, Inc. (ALLO) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-12
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
Confident tone
Regulatory designations and FDA engagement
ALLO-316 (Traverse / renal cell carcinoma)
Clinical site expansion / community access
Revenue
$4.64M
Diluted EPS
$-0.13
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Allogene Therapeutics, Inc. (ALLO) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Allogene Therapeutics, Inc. (ALLO) June 3, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-13
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript
Confident tone
Allo-329 autoimmune program
Semicel (cema-cel) Alpha-3 MRD interim analysis
MRD as treatment-decision paradigm / Natera Clarity assay
Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript
Positive tone
ALPHA-3 trial in LBCL
ALLO-329 in autoimmune disease
Data readouts and proof points
Revenue
$0*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript
Confident tone
ALLO-329 in autoimmune disease (Resolution study)
Allogeneic platform scalability vs autologous
ALPHA3 trial of cema-cel in first-line LBCL consolidation
Revenue
$0
Diluted EPS
$-0.19
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-13
Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript
Positive tone
ALPHA3 / cema-cel trial design change
ALLO-329 in autoimmune disease / RESOLUTION study
Allogeneic platform differentiation and durability
Revenue
$0
Diluted EPS
$-0.23
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript
Positive tone
ALPHA3 pivotal trial (cema-cel, 1L LBCL)
ALLO-329 RESOLUTION trial in autoimmune disease
ALLO-316 TRAVERSE trial in renal cell carcinoma
Revenue
$0
▼ 100% YoY Diluted EPS
$-0.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-13
Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript
Confident tone
ALLO-501A pivotal ALPHA3 trial in LBCL
ALLO-329 autoimmune expansion
Upcoming catalysts and trial milestones
Revenue
$0*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-02
Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript
Confident tone
ALLO-329 dual CAR for autoimmune disease
ALLO-316 in advanced renal cell carcinoma
ALPHA3 pivotal trial for cema-cel in first-line LBCL
Revenue
$0
▼ 100% YoY Diluted EPS
$-0.32
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call
Revenue
$0
▼ 100% YoY Diluted EPS
$-0.35
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript
Confident tone
Cema-cel / ALPHA3 pivotal trial in 1L LBCL
ALLO-329 autoimmune program with Dagger
ALLO-316 / TRAVERSE in renal cell carcinoma
Revenue
$22,000
▼ 26.7% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-14
Allogene Therapeutics, Inc. (ALLO) Q4 2023 Earnings Call Transcript
Confident tone
ALLO-329 autoimmune disease
CLL / ALPHA2 cohort
Corporate pivot and strategy
Revenue
$21,000*
▼ 19.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Allogene Therapeutics, Inc. (ALLO) Q3 2023 Earnings Call Transcript
Revenue
$22,000
▼ 18.5% YoY Diluted EPS
$-0.37
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Allogene Therapeutics, Inc. (ALLO) Q2 2023 Earnings Call Transcript
Revenue
$22,000
▼ 65.6% YoY Diluted EPS
$-0.54
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
Allogene Therapeutics, Inc. (ALLO) Q1 2023 Earnings Call Transcript
Revenue
$30,000
▼ 23.1% YoY Diluted EPS
$-0.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Allogene Therapeutics, Inc. (ALLO) Q4 2022 Earnings Call Transcript
Revenue
$26,000*
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
Allogene Therapeutics, Inc. (ALLO) Q3 2022 Earnings Call Transcript
Revenue
$27,000
▼ 44.9% YoY Diluted EPS
$-0.59
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Allogene Therapeutics, Inc. (ALLO) Q2 2022 Earnings Call Transcript
Revenue
$64,000
▲ 45.5% YoY Diluted EPS
$-0.56
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Allogene Therapeutics, Inc. (ALLO) Q1 2022 Earnings Call Transcript
Revenue
$39,000
▼ 99.9% YoY Diluted EPS
$-0.56
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Allogene Therapeutics, Inc. (ALLO) Q4 2021 Earnings Call Transcript
Revenue
$75.65M*
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Allogene Therapeutics, Inc. (ALLO) Q3 2021 Earnings Call Transcript
Revenue
$49,000
Diluted EPS
$-0.57
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Allogene Therapeutics, Inc. (ALLO) Q2 2021 Earnings Call Transcript
Revenue
$44,000
Diluted EPS
$-0.53
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Allogene Therapeutics, Inc. (ALLO) Q1 2021 Earnings Call Transcript
Revenue
$38.34M
Diluted EPS
$-0.25
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Allogene Therapeutics, Inc. (ALLO) Q4 2020 Earnings Call Transcript
Revenue
$0*
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Allogene Therapeutics, Inc. (ALLO) Q3 2020 Earnings Call Transcript
Revenue
$0
Diluted EPS
$-0.52
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Allogene Therapeutics, Inc. (ALLO) Q2 2020 Earnings Call Transcript
Revenue
$0
Diluted EPS
$-0.53
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Allogene Therapeutics, Inc. (ALLO) Q1 2020 Earnings Call Transcript
Revenue
$0
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Allogene Therapeutics, Inc. (ALLO) Q4 2019 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Showing 1–34 of 34 webcasts
Key facts
CIK
1737287
CUSIP
019770106
13F (30d)
158 filings
136 filers
Visit website
Investor relations